TransMedics (Nasdaq:TMDX) this week announced fourth-quarter results that beat the overall consensus on Wall Street.
The Andover, Massachusetts-based company reported profit losses of $6.7 million, or -21¢ per share, on sales of $31.4 million, for the three months ended Dec. 31, 2022, for a sales growth of 224.52% compared to Q4 2021. NuVasive also reported profit gains year-over-year when it reported $12.7 million in losses.
Earnings per share were 11¢ ahead of The Street, where analysts were looking for sales of $23.6 million.
“2022 was a transformative year for TransMedics as we delivered exceptional 209% revenue growth. We strongly believe that we are in the early stage of a long sustained growth period for our business and organ transplantation in the U.S.,” President and CEO Waleed Hassanein said in a news release. “We are now laser-focused on scaling our production capacity and NOP clinical and logistics infrastructure to achieve this goal.”
For full-year 2023, TransMedics anticipates revenue to be in the range of $138 million to $145 million to represent 48-55% growth year-over-year.
Shares in TMDX were up 13.91% to $73.52 apiece. MassDevice’s Medtech 100 Index was up more than 8%.
